Precision Biosciences director Buehler buys $21k in shares

Published 27/06/2025, 11:18
Precision Biosciences director Buehler buys $21k in shares

Director Kevin Buehler of Precision Biosciences INC (NASDAQ:DTIL) recently purchased 5,076 shares of common stock, according to a Form 4 filing. The transactions, which occurred on June 25, 2025, involved a total value of $21,116. The purchase comes as the stock has declined about 14% over the past week, though InvestingPro analysis suggests the shares are currently undervalued.

The price per share for the purchase ranged from $4.16 to $4.18. Following the transaction, Buehler directly owns 28,137 shares of Precision Biosciences. With a market capitalization of $46 million and analyst price targets ranging from $13 to $60, the company maintains a strong financial health score according to InvestingPro, which offers 8 additional key insights about DTIL’s financial position.

In other recent news, Precision BioSciences announced significant regulatory advancements for its gene editing therapies. The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Precision’s PBGENE-DMD therapy for Duchenne muscular dystrophy. This designation may qualify the company for a Priority Review Voucher upon potential FDA approval, which could expedite the review of another product. Additionally, Precision’s PBGENE-HBV therapy for chronic hepatitis B received Fast Track designation from the FDA, intended to accelerate its development and review process. The Fast Track designation underscores the urgent need for innovative treatments for chronic hepatitis B, affecting millions globally. At the company’s recent annual shareholder meeting, Kevin J. Buehler and Shari Lisa Piré were elected as Class III directors. Shareholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. However, a proposal to amend the Certificate of Incorporation did not pass, despite receiving substantial support. These developments highlight Precision BioSciences’ ongoing efforts in advancing its gene editing programs and corporate governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.